Cargando…

Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy

Membranous glomerulonephritis is the most common glomerular disease in adults. Its primary form has been characterized with formation of phospholipase A2 receptor antibodies. Malignancy, infections, and autoimmune disorders are the most common causes of secondary membranous glomerulonephritis. We pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Ramy M, Arman, Farid, Selamet, Umut, Wallace, William D, Barsoum, Marina, Rastogi, Anjay, Nobakht, Niloofar, Shieh, Perry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689923/
https://www.ncbi.nlm.nih.gov/pubmed/31448123
http://dx.doi.org/10.1177/2050313X19869764
_version_ 1783443116138692608
author Hanna, Ramy M
Arman, Farid
Selamet, Umut
Wallace, William D
Barsoum, Marina
Rastogi, Anjay
Nobakht, Niloofar
Shieh, Perry
author_facet Hanna, Ramy M
Arman, Farid
Selamet, Umut
Wallace, William D
Barsoum, Marina
Rastogi, Anjay
Nobakht, Niloofar
Shieh, Perry
author_sort Hanna, Ramy M
collection PubMed
description Membranous glomerulonephritis is the most common glomerular disease in adults. Its primary form has been characterized with formation of phospholipase A2 receptor antibodies. Malignancy, infections, and autoimmune disorders are the most common causes of secondary membranous glomerulonephritis. We present a case of a 55-year-old African American female who presented with nephrotic range proteinuria and diagnosed with secondary membranous glomerulonephritis based on distinct pathological features on kidney biopsy and absence of serum phospholipase A2 receptor antibodies. She initially underwent extensive workup for malignancies, infections, and common autoimmune disorders which were all negative. Her proteinuria remained resistant to steroid treatment and she was treated with subcutaneous adrenocorticotropic hormone injections. Meanwhile, she was also diagnosed with the anti-muscle specific kinase antibody variant of myasthenia gravis. In literature, there are few case reports of myasthenia gravis as a cause of secondary membranous glomerulonephritis. In our case, the lack of other inciting factors also suggested this association.
format Online
Article
Text
id pubmed-6689923
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-66899232019-08-23 Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy Hanna, Ramy M Arman, Farid Selamet, Umut Wallace, William D Barsoum, Marina Rastogi, Anjay Nobakht, Niloofar Shieh, Perry SAGE Open Med Case Rep Case Report Membranous glomerulonephritis is the most common glomerular disease in adults. Its primary form has been characterized with formation of phospholipase A2 receptor antibodies. Malignancy, infections, and autoimmune disorders are the most common causes of secondary membranous glomerulonephritis. We present a case of a 55-year-old African American female who presented with nephrotic range proteinuria and diagnosed with secondary membranous glomerulonephritis based on distinct pathological features on kidney biopsy and absence of serum phospholipase A2 receptor antibodies. She initially underwent extensive workup for malignancies, infections, and common autoimmune disorders which were all negative. Her proteinuria remained resistant to steroid treatment and she was treated with subcutaneous adrenocorticotropic hormone injections. Meanwhile, she was also diagnosed with the anti-muscle specific kinase antibody variant of myasthenia gravis. In literature, there are few case reports of myasthenia gravis as a cause of secondary membranous glomerulonephritis. In our case, the lack of other inciting factors also suggested this association. SAGE Publications 2019-08-08 /pmc/articles/PMC6689923/ /pubmed/31448123 http://dx.doi.org/10.1177/2050313X19869764 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Hanna, Ramy M
Arman, Farid
Selamet, Umut
Wallace, William D
Barsoum, Marina
Rastogi, Anjay
Nobakht, Niloofar
Shieh, Perry
Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy
title Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy
title_full Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy
title_fullStr Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy
title_full_unstemmed Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy
title_short Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy
title_sort secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689923/
https://www.ncbi.nlm.nih.gov/pubmed/31448123
http://dx.doi.org/10.1177/2050313X19869764
work_keys_str_mv AT hannaramym secondarymembranousnephropathyinapatientwithmyastheniagraviswithoutthymicdiseaseandpartialremissioninducedbyadrenocorticotropichormonetherapy
AT armanfarid secondarymembranousnephropathyinapatientwithmyastheniagraviswithoutthymicdiseaseandpartialremissioninducedbyadrenocorticotropichormonetherapy
AT selametumut secondarymembranousnephropathyinapatientwithmyastheniagraviswithoutthymicdiseaseandpartialremissioninducedbyadrenocorticotropichormonetherapy
AT wallacewilliamd secondarymembranousnephropathyinapatientwithmyastheniagraviswithoutthymicdiseaseandpartialremissioninducedbyadrenocorticotropichormonetherapy
AT barsoummarina secondarymembranousnephropathyinapatientwithmyastheniagraviswithoutthymicdiseaseandpartialremissioninducedbyadrenocorticotropichormonetherapy
AT rastogianjay secondarymembranousnephropathyinapatientwithmyastheniagraviswithoutthymicdiseaseandpartialremissioninducedbyadrenocorticotropichormonetherapy
AT nobakhtniloofar secondarymembranousnephropathyinapatientwithmyastheniagraviswithoutthymicdiseaseandpartialremissioninducedbyadrenocorticotropichormonetherapy
AT shiehperry secondarymembranousnephropathyinapatientwithmyastheniagraviswithoutthymicdiseaseandpartialremissioninducedbyadrenocorticotropichormonetherapy